Cargando…

The cardiovascular polypill as baseline treatment improves lipid profile and blood pressure regardless of body mass index in patients with cardiovascular disease. The Bacus study

BACKGROUND: Pharmacological treatment with lipid-lowering and antihypertensive drugs has been proposed as a strategy to improve excess cardiovascular (CV) risk among obese individuals. The present study aimed to assess whether the CV polypill (Sincronium(®)) could be an effective strategy to help im...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chávez Fernández, José Alejandro, Ramírez Mendoza, Marcelo, Kassck Ipinaa, Hermelinda, Sánchez Ángeles, Luís Antonio, González Chávez, Antonio, Escobedo, Galileo, Méndez-García, Lucía Angélica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10456133/ https://www.ncbi.nlm.nih.gov/pubmed/37624820 http://dx.doi.org/10.1371/journal.pone.0290544

Ejemplares similares

Multifactorial Prevention of Cardiovascular Disease in Patients with Hypertension: the Cardiovascular Polypill
por: Lafeber, M., et al.
Publicado: (2016)

Strengths and Limitations of Using the Polypill in Cardiovascular Prevention
por: Roy, Ambuj, et al.
Publicado: (2017)

Medicinal herbs: Potential polypills in cardiovascular diseases
por: Noroozi, Samaneh, et al.
Publicado: (2021)

Statins alone or polypill for primary prevention of cardiovascular diseases
por: Hasani-Ranjbar, Shirin, et al.
Publicado: (2016)

Could patents interfere with the development of a cardiovascular polypill?
por: Beall, Reed F., et al.
Publicado: (2016)

The feasibility of polypill for cardiovascular disease prevention in Asian Population
por: Sukonthasarn, Apichard, et al.
Publicado: (2020)

Redefining the polypill: pros and cons in cardiovascular precision medicine
por: Birla, Siddharth, et al.
Publicado: (2023)

The polypill approach – An innovative strategy to improve cardiovascular health in Europe
por: Fuster, Valentín, et al.
Publicado: (2017)

The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population
por: van Gils, Paul F, et al.
Publicado: (2011)

Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease
por: Wood, Frances, et al.
Publicado: (2015)

Practical Decision Algorithms for the Use of the Cardiovascular Polypill in Secondary Prevention in Europe
por: Grigorian-Shamagian, Lilian, et al.
Publicado: (2021)

Adoption and scale-up of the cardiovascular Polypill: a realist institutional analysis
por: Abimbola, Seye, et al.
Publicado: (2022)

Polypills for Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis
por: Kandil, Omneya A., et al.
Publicado: (2022)

The Effectiveness of Polypill for the Prevention of Cardiovascular Disease: A Meta-Analysis of Randomized Controlled Trials
por: Virk, Ghazala S, et al.
Publicado: (2023)

Polypill—Friend or Foe?
por: Rishi, Rakesh Kumar
Publicado: (2011)

A Polypill for primary prevention of cardiovascular disease: A feasibility study of the World Health Organization
por: Soliman, Elsayed Z, et al.
Publicado: (2011)

Polypill for Population-Level Primary Cardiovascular Prevention in Underserved Populations—A Social Epidemiology Counterargument
por: Cainzos-Achirica, Miguel, et al.
Publicado: (2020)

Polypill for atherosclerotic cardiovascular disease prevention in Haiti: Eligibility estimates in a low-income country
por: Yan, Lily D., et al.
Publicado: (2022)

Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review
por: Lopez-Lopez, Jose P, et al.
Publicado: (2023)

Effect of the Polypill on Adherence and Prevention of Cardiovascular Diseases in Patients With or at High Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials
por: Memon, Rahat A, et al.
Publicado: (2023)

The Polypill: From Promise to Pragmatism
por: Huffman, Mark D.
Publicado: (2015)

Polypill revisited – Unity in diversity
por: Dan, Gheorghe-Andrei, et al.
Publicado: (2020)

Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients
por: Ros-Castelló, Victoria, et al.
Publicado: (2020)

Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst Indigenous and non Indigenous people at high cardiovascular risk
por: Liu, Hueiming, et al.
Publicado: (2010)

Would primary healthcare professionals prescribe a polypill to manage cardiovascular risk? A qualitative interview study
por: Virdee, Satnam K, et al.
Publicado: (2013)

Polypill Brings Benefits to Patients with Cardiovascular Disease, Both Improving Medication Adherence and Demonstrating the Concept of Chronotherapy [Letter]
por: Zhu, Ling-Ling, et al.
Publicado: (2023)

An International Randomised Placebo-Controlled Trial of a Four-Component Combination Pill (“Polypill”) in People with Raised Cardiovascular Risk
Publicado: (2011)

Economic Burden Associated with the Treatment with a Cardiovascular Polypill in Secondary Prevention in Spain: Cost-Effectiveness Results of the NEPTUNO Study
por: Cordero, Alberto, et al.
Publicado: (2023)

The use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease – expert panel meeting report
por: Grigorian-Shamagian, Lilian, et al.
Publicado: (2023)

Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event: the international VULCANO randomised clinical trial
por: Mostaza, José M., et al.
Publicado: (2022)

Correction: The use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease – expert panel meeting report
por: Grigorian-Shamagian, Lilian, et al.
Publicado: (2023)

Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK
por: Becerra, Virginia, et al.
Publicado: (2015)

Correction: An international randomised placebo-controlled trial of a four-component combination pill (“polypill”) in people with raised cardiovascular risk
Publicado: (2019)

Cost-effectiveness of fixed-dose combination pill (Polypill) in primary and secondary prevention of cardiovascular disease: A systematic literature review
por: Jahangiri, Reza, et al.
Publicado: (2022)

Cost-Effectiveness of the CNIC-Polypill Strategy Compared With Separate Monocomponents in Secondary Prevention of Cardiovascular and Cerebrovascular Disease in Portugal: The MERCURY Study
por: Aguiar, Carlos, et al.
Publicado: (2022)

The Benefits of Polypill: Adherence and Chronotherapy [Response to Letter]
por: Lopez-Jaramillo, Patricio, et al.
Publicado: (2023)

A cardiovascular polypill for secondary stroke prevention in a tertiary centre in Ghana (SMAART): a phase 2 randomised clinical trial
por: Sarfo, Fred Stephen, et al.
Publicado: (2023)

Correction: Cost-effectiveness of fixed-dose combination pill (Polypill) in primary and secondary prevention of cardiovascular disease: A systematic literature review
por: Jahangiri, Reza, et al.
Publicado: (2023)

HbA1c variability predicts cardiovascular complications in type 2 diabetes regardless of being at glycemic target
por: Ceriello, Antonio, et al.
Publicado: (2022)

„Polypill“ in der kardiovaskulären Prävention – erfolgreich durch Vereinfachung?: Neue Studienergebnisse zum Nutzen der Polypill-Strategie in der Primär- und Sekundärprävention
por: Despang, Patrick, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lg9knhfvqicfht42qn5hejkrp7